REDWOOD CITY, Calif.,
Oct. 16, 2019 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced an upcoming presentation at
the Annual Meeting of the American Society of
Anesthesiologists.
Dr. Gan will present and lead a discussion around acute pain and
an alternative approach to pain management. Patients often report
moderate-to-severe pain following procedures or surgery. In the
recovery room, there are potential complications associated with
uncontrolled pain, including extended PACU time and increased
readmission rates. An innovative advance in opioid analgesia has
recently been approved and may offer potential advantages where
there may be postoperative limitations.
"I'm pleased to present a new innovative option for managing
moderate-to-severe acute pain as part of the Enhanced Recovery
strategy as it is consistent with our objective with moving away
from invasive modalities," said Dr. Gan.
Details on the
presentation are as follows:
|
Title:
|
Matching the PK and
the Pain Profiles: An Innovative Approach to Analgesia in the
PACU
|
Presenter:
|
Dr. TJ Gan, MD, MBA,
MHS, FRCA (UK), FRCA (Ire), LicAc
|
|
Professor and
Chairman, Department of Anesthesiology
|
|
Stony Brook
University Renaissance School of Medicine
|
Date/Time:
|
Sunday, October 20,
2019; 12:00pm-1:00pm ET
|
Location:
|
Orange County
Convention Center, Orlando, FL, Room 415A
|
Dr. TJ Gan is Professor and Chairman of the Department of
Anesthesiology at Stony Brook University Renaissance School of
Medicine in Stony Brook, New York.
Previously, Dr. Gan was Professor of Anesthesiology and Vice
Chairman for Clinical Research and Faculty Development at
Duke University. Dr. Gan received his
medical training at the London Hospital Medical College of the
University of London. He has
attained licensure in acupuncture from the British College of
Acupuncture and a Master in Clinical Research as well as a Master
in Business Administration (MBA).
Dr. Gan is the Founding President of the American Society for
Enhanced Recovery (ASER), President of the Perioperative Quality
Initiative (POQI), a Past President of the Society for Ambulatory
Anesthesia (SAMBA) and the International Society for Anesthetic
Pharmacology (ISAP). Dr. Gan is also a Council Member of the
Association of Academic Anesthesiology Chairs (AAAC). He has
published over 250 manuscripts in peer-reviewed journals and
numerous books and books chapters. Dr. Gan has served as an invited
speaker for many national and international professional
conferences and as principal investigator or co-investigator for
over 100 clinical trials, with total awarded grant funding of more
than $23 million, focusing on
enhanced recovery, postoperative nausea and vomiting, as well as
pain, fluid and hemodynamic management, and anesthetic
pharmacology.
The American Society of Anesthesiology's annual meeting unites
more than 14,000 clinicians, thought leaders, and professionals
from around the world. For more information, please visit:
https://www.asahq.org/annualmeeting.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's proprietary,
non-invasive sublingual formulation technology delivers sufentanil
with consistent pharmacokinetic profiles. The Company has one
approved product in the U.S., DSUVIA® (sufentanil sublingual
tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute
pain severe enough to require an opioid analgesic for adult
patients in certified medically supervised healthcare settings, and
one product candidate, Zalviso®(sufentanil sublingual tablet
system, SST system, 15 mcg) being developed as an innovatively
designed patient-controlled analgesia (PCA) system for reduction of
moderate-to-severe acute pain in medically supervised settings.
DZUVEO and Zalviso are both approved products in Europe. Zalviso is not approved in the U.S.
For additional information about AcelRx, please visit
www.acelrx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dr-tj-gan-to-present-at-the-2019-annual-meeting-of-the-american-society-of-anesthesiologists-300939301.html
SOURCE AcelRx Pharmaceuticals, Inc.